Clinical Trials · NCT04889183

SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

CompletedPhase 3Semaglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
University Medical Center Groningen
Enrollment
125
Start date
Mar 2022
Locations
13 sites, 4 countries
Primary endpoint
Change from baseline to week 24 in urinary albumin:creatinine ratio (UACR)
View Semaglutide compound reference